EP2817295A4 - Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4 - Google Patents

Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4

Info

Publication number
EP2817295A4
EP2817295A4 EP13751391.7A EP13751391A EP2817295A4 EP 2817295 A4 EP2817295 A4 EP 2817295A4 EP 13751391 A EP13751391 A EP 13751391A EP 2817295 A4 EP2817295 A4 EP 2817295A4
Authority
EP
European Patent Office
Prior art keywords
aminothieno
pyridazine
substituted
acetylcholine receptor
positive allosteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13751391.7A
Other languages
English (en)
French (fr)
Other versions
EP2817295A1 (de
EP2817295B1 (de
Inventor
Craig W Lindsley
P Jeffrey Conn
Michael R Wood
Bruce J Melancon
James C Tarr
James M Salovich
Michael S Poslusney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to EP17199020.3A priority Critical patent/EP3321257A1/de
Publication of EP2817295A1 publication Critical patent/EP2817295A1/de
Publication of EP2817295A4 publication Critical patent/EP2817295A4/de
Application granted granted Critical
Publication of EP2817295B1 publication Critical patent/EP2817295B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13751391.7A 2012-02-23 2013-02-23 Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4 Active EP2817295B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP17199020.3A EP3321257A1 (de) 2012-02-23 2013-02-23 Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602481P 2012-02-23 2012-02-23
PCT/US2013/027534 WO2013126856A1 (en) 2012-02-23 2013-02-23 Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP17199020.3A Division EP3321257A1 (de) 2012-02-23 2013-02-23 Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4

Publications (3)

Publication Number Publication Date
EP2817295A1 EP2817295A1 (de) 2014-12-31
EP2817295A4 true EP2817295A4 (de) 2015-08-26
EP2817295B1 EP2817295B1 (de) 2017-11-01

Family

ID=49006287

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17199020.3A Withdrawn EP3321257A1 (de) 2012-02-23 2013-02-23 Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4
EP13751391.7A Active EP2817295B1 (de) 2012-02-23 2013-02-23 Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP17199020.3A Withdrawn EP3321257A1 (de) 2012-02-23 2013-02-23 Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4

Country Status (4)

Country Link
US (2) US9493481B2 (de)
EP (2) EP3321257A1 (de)
ES (1) ES2656972T3 (de)
WO (1) WO2013126856A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491038B1 (de) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituierte octahy-dropyrrolo [3,4-c]pyrrole als orexinrezeptormodulatoren
PE20140011A1 (es) 2010-09-03 2014-01-31 Forma Tm Llc Compuestos y composiciones novedosos para la inhibicion de nampt
US9586962B2 (en) * 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
WO2013126856A1 (en) * 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2014149819A1 (en) 2013-03-14 2014-09-25 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
WO2015027214A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2015089170A1 (en) 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Bicyclic alkyl compounds and synthesis
CN106232567B (zh) 2014-03-07 2021-11-02 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
CN106536518B (zh) * 2014-05-19 2020-05-12 勃林格殷格翰动物保健美国公司 驱蠕虫化合物
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
WO2016179351A1 (en) 2015-05-05 2016-11-10 Northwestern University Treatment of levodopa-induced dyskinesias
EP3394061B1 (de) 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. Allosterische 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-on-modulatoren des m4-muskarinischen acetylcholinrezeptors
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
CA2960253A1 (en) 2016-03-10 2017-09-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
MA45463A (fr) 2016-06-22 2019-05-01 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
HUE054857T2 (hu) 2016-07-01 2021-10-28 Pfizer 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
US10342782B2 (en) 2016-07-27 2019-07-09 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
BR112018007755A2 (pt) * 2016-08-18 2018-10-23 Univ Vanderbilt moduladores alostéricos positivos do receptor muscarínico m4 de acetilcolina
US10189857B2 (en) 2016-09-13 2019-01-29 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
JP7099725B2 (ja) 2016-11-07 2022-07-12 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
MA46899A (fr) 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
EP3534901B1 (de) 2016-11-07 2022-06-22 Vanderbilt University Positive allosterische modulatoren des muskarinischen acetylcholinrezeptors m4
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
EP3366683A1 (de) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Zyklische amide, acetamide und harnstoffe als kalium kanal öffner
KR102296703B1 (ko) 2017-03-20 2021-09-01 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
JP7157769B2 (ja) 2017-05-15 2022-10-20 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 鎮痛剤化合物
US11065235B2 (en) 2017-05-19 2021-07-20 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof
DK3642202T3 (da) 2017-06-22 2023-01-30 Pfizer Dihydro-pyrrolo-pyridin-derivater
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
EP3704126A4 (de) 2017-11-03 2020-12-09 Université de Montréal Verbindungen und verwendung davon in der expansion von stammzellen und/oder vorläuferzellen
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
US11376254B2 (en) 2017-12-05 2022-07-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
GB202018412D0 (en) * 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
MX2023011269A (es) 2021-03-23 2024-01-17 Bioage Labs Inc Inhibidores del inflamasoma nlrp3.
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
US11787805B2 (en) 2022-01-28 2023-10-17 BioAge Labs, Inc. N-oxide inhibitors of NLRP3 inflammasome
CN115246842B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类靶向去泛素化酶usp25和usp28的小分子抑制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496725A (en) * 1983-05-23 1985-01-29 The Dow Chemical Company Substituted 1,2,3-triazino[4',5':4,5]-thieno[2,3-B]quinolin-4(3H)-ones
JPH0776586A (ja) 1993-07-16 1995-03-20 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物
JP4176147B2 (ja) 1995-07-28 2008-11-05 アボツト・ラボラトリーズ 化学的シナプス伝達の制御に有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
PT1807434E (pt) * 2004-10-25 2010-09-22 Lilly Co Eli Tienopiridinas a título de potenciadores alostéricos do receptor muscarínicom4
US20070049603A1 (en) 2005-09-01 2007-03-01 Greg Miknis Raf inhibitor compounds and methods of use thereof
EP2038289A2 (de) 2006-04-21 2009-03-25 Amgen Inc. Thieno-[2,3-d]pyrimidin- und thieno-pyridazinverbindungen und anwendungsverfahren
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
US20110077250A1 (en) * 2009-06-26 2011-03-31 Ryder Sean Compounds for modulating rna binding proteins and uses therefor
WO2011063415A2 (en) 2009-11-23 2011-05-26 Afraxis, Inc. Methods for treating mild cognitive impairment
WO2011163280A1 (en) 2010-06-21 2011-12-29 Vanderbilt University Indole compounds as positive allosteric modulators of the muscarinic receptor
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
WO2012154731A1 (en) 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2013049255A1 (en) 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
WO2013126856A1 (en) 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2014035829A1 (en) 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
WO2015027214A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
A. E. BRADY ET AL: "Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 327, no. 3, 5 September 2008 (2008-09-05), pages 941 - 953, XP055081736, ISSN: 0022-3565, DOI: 10.1124/jpet.108.140350 *
ABBADY, M. S. ET AL: "Synthesis and some reactions of thieno[2,3-c]pyridazine derivatives and their antibacterial activity", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 86, no. 1-4, 1994, pages 203 - 209, XP009184922, ISSN: 1042-6507, DOI: 10.1080/10426509408018405 *
AL-KAMALI, AHMED S. N. ET AL: "Synthesis and antibacterial activity of some novel thieno[2,3-c]pyridazines using 3-amino-5-phenyl-2-ethoxycarbonylthieno[2,3- c]pyridazine as a starting material", ARABIAN JOURNAL OF CHEMISTRY, vol. 7, no. 5, 2014, pages 775 - 780, XP002741787, ISSN: 1878-5352, DOI: 10.1016/J.ARABJC.2010.12.020 *
AL-KAMALI, AHMED S. N.: "Synthesis and reactions of some new thieno[2,3-C]pyridazine derivatives", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 184, no. 7, 2009, pages 1812 - 1824, XP002741779, ISSN: 1042-6507, DOI: 10.1080/10426500802353213 *
EL-DEAN, A. M. KAMAL ET AL: "Novel synthesis of thieno[2,3-c]pyridazine and pyrimido[4',5':4,5]thieno[2,3-c]pyridazine derivatives", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 180, no. 2, 2005, pages 413 - 424, XP002741781, ISSN: 1042-6507, DOI: 10.1080/104265090509216 *
GABER, ABD EL-AAL M. ET AL: "Synthesis of novel polyfunctionally substituted thieno[2,3-c]pyridazines", JOURNAL OF THE CHINESE CHEMICAL SOCIETY (TAIPEI, TAIWAN), vol. 51, no. 6, 2004, pages 1325 - 1331, XP002741783, ISSN: 0009-4536, DOI: 10.1002/JCCS.200400192 *
J. PHILLIP KENNEDY ET AL: "Synthesis and Structure-Activity Relationships of Allosteric Potentiators of the M 4 Muscarinic Acetylcholine Receptor", CHEMMEDCHEM, vol. 4, no. 10, 5 October 2009 (2009-10-05), pages 1600 - 1607, XP055081738, ISSN: 1860-7179, DOI: 10.1002/cmdc.200900231 *
RADWAN, SH. M. ET AL: "Synthesis of pyridazothienothiazine and pyrimidothienopyridazines", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 164, 2000, pages 299 - 313, XP002741782, ISSN: 1042-6507, DOI: 10.1080/10426500008045255 *
RADWAN, SH. M. ET AL: "Synthesis of pyrrolo[1",2":1',2']pyrazino[6',5':4,5]thieno[2,3- c]pyridazine derivatives and related pentacyclic heterocycles", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS , 89(1-4), 193-8 CODEN: PSSLEC; ISSN: 1042-6507, 1994, XP009184919, DOI: 10.1080/10426509408020449 10.1080/10426509408020449 *
RADWAN, SH. M. ET AL: "Synthesis of some new pyrimidothienopyridazines and related heterocycles", JOURNAL OF THE CHINESE CHEMICAL SOCIETY (TAIPEI, TAIWAN), vol. 52, no. 2, 2005, pages 303 - 308, XP002741780, ISSN: 0009-4536, DOI: 10.1002/JCCS.200500046 *
RADWAN, SH. M.: "Synthesis and reactions of some new heterocyclic compounds containing thieno[2,3-c]pyridazine moiety", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS , 163, 153-169 CODEN: PSSLEC; ISSN: 1042-6507, vol. 163, 2000, pages 153 - 169, XP008169735, ISSN: 1042-6507, DOI: 10.1080/10426500008046617 *
See also references of WO2013126856A1 *

Also Published As

Publication number Publication date
WO2013126856A1 (en) 2013-08-29
EP2817295A1 (de) 2014-12-31
US9493481B2 (en) 2016-11-15
ES2656972T3 (es) 2018-03-01
US20170022216A1 (en) 2017-01-26
US9868746B2 (en) 2018-01-16
US20150018309A1 (en) 2015-01-15
EP3321257A1 (de) 2018-05-16
EP2817295B1 (de) 2017-11-01

Similar Documents

Publication Publication Date Title
EP2817295A4 (de) Substituierte 5-aminothieno-[2,3-c-]pyridazin-6-carboxamidanaloga als positive allosterische modulatoren des muskarinacetylcholinrezeptors m4
IL266285B (en) Methods for the production of thiano [d – 3,2] pyrimidine compounds
HK1232219A1 (zh) 作為趨化因子受體調節劑的硫衍生物
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
PT2770997T (pt) Análogos de 2-(4-heterociclilbenzil)isoindolin-1-ona substituídos como moduladores alostéricos positivos do receptor m1 de acetilcolina muscarínico
EP2663550A4 (de) Substituierte benzoazepine als toll-like-rezeptor-modulatoren
EP2663555A4 (de) Substituierte benzoazepine als toll-like-rezeptor-modulatoren
IL228260B (en) Oligonucleotide modulators of the toll-like receptor pathway
EP2675722A4 (de) Durchstechkappe
ZA201403381B (en) Moisturizing composition comprising an aminopeptide mixture
HK1191330A1 (en) Ethynyl derivatives as positive allosteric modulators of the mglur5 mglur5
EP2879669A4 (de) Antagonisten des toll-like-rezeptor-1/2-komplexes
EP2931737A4 (de) Mischung aus fucosylatlactosen
EP2660163A4 (de) Gummistopfen für fläschchen
HK1259248A1 (zh) 作為趨化因子受體調節劑的新的1，2-雙-磺醯胺衍生物
HUE038700T2 (hu) Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk
HK1200821A1 (en) 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators gpbar1 12-16--
AU2012900472A0 (en) Carpobrotus 'CAR 10'
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
GB201201894D0 (en) 'Hammerheadz' flip flops
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL398695A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
AU2012903933A0 (en) Chaz's Knotchamacallit
PL398984A1 (pl) Sposób wytwarzania (Z)-6,4'-dihydroksy-4-metoksy-7- prenyloauronu

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5025 20060101ALI20150716BHEP

Ipc: C07D 409/02 20060101ALI20150716BHEP

Ipc: C07D 237/26 20060101AFI20150716BHEP

Ipc: C07D 495/04 20060101ALI20150716BHEP

Ipc: A61P 25/28 20060101ALI20150716BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150728

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5025 20060101ALI20150721BHEP

Ipc: A61P 25/28 20060101ALI20150721BHEP

Ipc: C07D 409/02 20060101ALI20150721BHEP

Ipc: C07D 237/26 20060101AFI20150721BHEP

Ipc: C07D 495/04 20060101ALI20150721BHEP

17Q First examination report despatched

Effective date: 20160613

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170223

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VANDERBILT UNIVERSITY

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TARR, JAMES, C.

Inventor name: POSLUSNEY, MICHAEL, S.

Inventor name: CONN, P., JEFFREY

Inventor name: WOOD, MICHAEL, R.

Inventor name: SALOVICH, JAMES, M.

Inventor name: MELANCON, BRUCE, J.

Inventor name: LINDSLEY, CRAIG, W.

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170510

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 941869

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013028762

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2656972

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180301

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20171101

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 941869

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180201

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180201

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180202

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180301

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013028762

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

26N No opposition filed

Effective date: 20180802

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180223

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130223

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240301

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240228

Year of fee payment: 12

Ref country code: GB

Payment date: 20240227

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240222

Year of fee payment: 12

Ref country code: FR

Payment date: 20240226

Year of fee payment: 12